MBX Biosciences doses first patient in Phase 3 oPTimize trial
MBX Biosciences has dosed the first patient in its Phase 3 oPTimize trial of once-weekly canvuparatide.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
MBX Biosciences first patient dosed in Phase 3 oPTimize trial
MBX Biosciences announced first patient dosed in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for adults with hypoparathyroidism.